myelodysplastic syndromes (MDS) | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

I Was Alone With MDS Until I Connected With Others on Social Media

Person's Name: 
Jane Biehl, PhD

I sat quietly in the oncologist’s office. The doctor confirmed that my diagnosis was MDS and calmly stated, “The average survival term for your kind of MDS is 104 months.” I felt the room spin.

 

I never have been healthy, and suffered from upper respiratory infections all my life. Kidney and bladder infections plagued me all through college, and I have had a severe hearing loss since birth. I had been diagnosed in 1986 with an IGA deficiency, meaning that I had insufficient immunity although I was treated symptomatically with antibiotics when needed.

 

Bone Marrow Diseases: 

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s): 
Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R
Primary Author: 
Slade M
Journal Title: 
Biology of Blood and Marrow Transplantation
Original Publication Date: 
Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

Author(s): 
Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
Primary Author: 
Ali AM
Journal Title: 
Cancer Med
Original Publication Date: 
Oct 2017

Bone Marrow Diseases: 

Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

Author(s): 
DeZern AE, Binder G, Ni Q, McGuire M, Smith BD
Primary Author: 
DeZern AE
Journal Title: 
Leuk Res
Original Publication Date: 
Oct 2017

Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with

Bone Marrow Diseases: 

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

Author(s): 
Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U
Primary Author: 
Balaian E
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2017

The effects of

Bone Marrow Diseases: 

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 -
8:00am to 3:30pm
Conference Event Type: 

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

Author(s): 
Mies A, Platzbecker U
Primary Author: 
Mies A
Journal Title: 
Semin Hematol
Original Publication Date: 
Jul 2017

Patients with lower-risk

Bone Marrow Diseases: 

Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

Author(s): 
Madanat Y, Sekeres MA
Primary Author: 
Madanat Y
Journal Title: 
Semin Hematol
Original Publication Date: 
Jun 2017

Bone Marrow Diseases: